PMID- 9258068
OWN - NLM
STAT- MEDLINE
DCOM- 19970916
LR  - 20211203
IS  - 0022-5347 (Print)
IS  - 0022-5347 (Linking)
VI  - 158
IP  - 3 Pt 1
DP  - 1997 Sep
TI  - C-met proto-oncogene expression in benign and malignant human renal tissues.
PG  - 724-8
AB  - PURPOSE: Hepatocyte growth factor/scatter factor (HGF/SF) is a potent mitogen to 
      renal epithelial cells in vitro and in vivo. HGF/SF signals through its receptor 
      which is coded by the c-met proto-oncogene. We hypothesized that altered 
      expression of the HGF/SF receptor, c-met, may be involved in the pathogenesis of 
      certain renal cell carcinomas. Our objectives were to 1) assess the presence and 
      localization of c-met protein in benign and malignant human renal tissues, and 2) 
      correlate the presence of c-met protein with renal carcinoma histological 
      subtype, tumor stage and tumor grade. MATERIALS AND METHODS: Immunohistochemical 
      analysis of c-met protein was performed in 41 normal and malignant human renal 
      samples. RESULTS: c-met Immunostaining was detected in the normal kidney tissue 
      in all 41 samples. In the normal kidney c-met immunostaining was limited to the 
      cell membrane and/or cytoplasm of epithelial cells in specific tubular segments, 
      including the proximal convoluted tubule, thin and thick limbs of the loop of 
      Henle, and the collecting duct. The glomeruli, distal convoluted tubule and 
      stroma were consistently negative for c-met staining. c-met Immunostaining was 
      detected in 68% of renal cell carcinomas and was more common in higher nuclear 
      grade cancers (p < 0.034). CONCLUSIONS: The c-met receptor is present in specific 
      tubular segments in the normal kidney and is frequently expressed in higher 
      nuclear grade renal cancers, suggesting a role in renal carcinoma progression. 
      Future studies should evaluate the biological significance of the HGF/ SF-c-met 
      pathway in normal renal physiology, and renal cancer growth and progression.
FAU - Pisters, L L
AU  - Pisters LL
AD  - Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston 
      77030, USA.
FAU - el-Naggar, A K
AU  - el-Naggar AK
FAU - Luo, W
AU  - Luo W
FAU - Malpica, A
AU  - Malpica A
FAU - Lin, S H
AU  - Lin SH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Receptors, Growth Factor)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
SB  - IM
MH  - Carcinoma, Renal Cell/*genetics/pathology
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Hepatocyte Growth Factor/*genetics
MH  - Humans
MH  - Kidney Neoplasms/*genetics/pathology
MH  - Neoplasm Staging
MH  - Proto-Oncogene Mas
MH  - Proto-Oncogene Proteins/*biosynthesis/genetics
MH  - Receptors, Growth Factor/*biosynthesis/genetics
MH  - Retrospective Studies
EDAT- 1997/09/01 00:00
MHDA- 1997/09/01 00:01
CRDT- 1997/09/01 00:00
PHST- 1997/09/01 00:00 [pubmed]
PHST- 1997/09/01 00:01 [medline]
PHST- 1997/09/01 00:00 [entrez]
AID - S0022-5347(01)64301-5 [pii]
AID - 10.1097/00005392-199709000-00009 [doi]
PST - ppublish
SO  - J Urol. 1997 Sep;158(3 Pt 1):724-8. doi: 10.1097/00005392-199709000-00009.